Grimes & Company’s ImmunityBio IBRX Stock Holding History

Grimes & Company’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$409K	Sell	53,307 -5,129	-9%	-$35.1K	0.01%	322
2025 Q4	$116K	Hold	58,436	–	–	﹤0.01%	451
2025 Q3	$144K	Hold	58,436	–	–	﹤0.01%	443
2025 Q2	$154K	Buy	58,436 +48,436	+484%	+$130K	﹤0.01%	404
2025 Q1	$30.1K	Hold	10,000	–	–	﹤0.01%	366
2024 Q4	$25.6K	Hold	10,000	–	–	﹤0.01%	379
2024 Q3	$37.2K	Hold	10,000	–	–	﹤0.01%	359
2024 Q2	$63.2K	Hold	10,000	–	–	﹤0.01%	340
2024 Q1	$53.7K	Hold	10,000	–	–	﹤0.01%	335
2023 Q4	$50.2K	Hold	10,000	–	–	﹤0.01%	322
2023 Q3	$16.9K	Hold	10,000	–	–	﹤0.01%	304
2023 Q2	$27.8K	Buy	+10,000	New	+$28.3K	﹤0.01%	306

Other funds holding IBRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments

Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $26B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return